Pregnancy is an exciting and amazing journey, but it comes with its share of health checks. One such concern that expecting mothers with Rh-negative blood groups may face is Rh incompatibility with the fetus. This condition can affect your baby’s health if not monitored early. However, with the right testing and care, complications can be avoided. That’s where MedGenome’s Rhesus D Track test steps in, offering a non-invasive way to ensure both you and your baby remain safe throughout the pregnancy.

What is Rh Incompatibility?

The Rh factor refers to a specific protein found on the surface of red blood cells. If your blood red blood cells haves this protein, you are Rh-positive. If it doesn’t, you are Rh-negative. While this difference doesn’t affect day-to-day health, it becomes a concern during pregnancy. If an Rh-negative mother carries an Rh-positive baby, it can lead to Rh incompatibility, usually in subsequent pregnancies.

In such cases, the mother’s body might produce antibodies that attack the baby’s Rh-positive red blood cells. This response can cause various complications for the baby, including hemolytic disease, which can be severe.

Causes of Rh Incompatibility

Rh incompatibility in pregnancy occurs mainly due to the difference in Rh factor between the mother and baby. This mismatch causing Rh incompatibility happens when:

• The mother is Rh-negative, but the father is Rh-positive.
• The baby inherits the Rh-positive factor from the father.

During the first pregnancy, Rhesus incompatibility usually does not cause significant problems, as the mother’s body may not have had enough exposure to the baby’s Rh-positive blood. However, in future pregnancies, the risk increases because the mother’s immune system becomes sensitized to the Rh factor, making it likely to produce antibodies.

Risk Factors/Complications of Rh Incompatibility

The complications of Rh incompatibility typically worsen with each pregnancy if no preventive steps are taken. The body creates antibodies after being exposed to Rh-positive blood, either through previous pregnancy, miscarriage, or blood transfusion. These antibodies can attack the baby’s red blood cells, leading to complications such as:

• Hemolytic disease of the newborn (HDN): The baby’s red blood cells are destroyed faster than they can be replaced.
• Anemia: The loss of red blood cells can cause severe anemia in the baby.
• Jaundice: When red blood cells break down, a substance known as bilirubin is released, leading to jaundice.
• Heart failure or death in extreme cases.

Though Rh incompatibility poses these risks, the advancement in RhD testing and early intervention has significantly reduced the severity of these complications.

-Second Pregnancy Complications

The risk of complications rises in a second pregnancy if the first child is Rh-positive. In such cases, the mother’s immune system is already sensitized, meaning it has developed antibodies that could move across the placenta and attack the red blood cells of the next Rh-positive baby..

Diagnosis of Rh Incompatibility

Early diagnosis of Rh incompatibility is crucial to ensure a healthy pregnancy. Pregnant women undergo a routine blood test in their first trimester to determine their Rh status. If the mother is Rh-negative and the father is Rh-positive, further monitoring and testing become necessary.

Doctors will perform tests to check for:

• Blood antibody levels to determine if the mother has developed antibodies against the baby’s red blood cells.
• Serial Ultrasound with Doppler studies – to detect fetal anaemia non-invasively.

With these tests, healthcare providers can predict the severity of Rhesus incompatibility and take the necessary steps to prevent complications.

How MedGenome’s Rhesus D Track Test Can Help?

MedGenome offers an advanced solution for detecting Rh incompatibility in expecting mothers through its Rhesus D Track test. This non-invasive prenatal test (NIPT) uses a simple blood sample from the mother to determine the baby’s RhD status early in pregnancy, allowing for timely intervention. Here’s how it works:

• Real-time quantitative PCR method: This innovative approach accurately detects the RhD status of the fetus using cell-free fetal DNA from the mother’s blood.
• It helps RhD-negative women, as it allows them to avoid unnecessary preventive treatments if the baby is found to be Rh-negative.

The test is sensitive, safe, and convenient and eliminates the risks associated with invasive diagnostic methods. This helps doctors decide whether Rh immunoglobulin treatment is necessary during pregnancy, thus preventing Rh sensitization and the complications it brings. It is based on the latest molecular testing methods, ensuring precise and reliable information.

Conclusion